SCHEMBL12155626

SCHEMBL12155626

O=C(Nc1ccc(-c2cc3c(cc2Br)OCO3)cn1)c1ncccc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 10/20 0.43
▸ RAB9A P51151 10/20 0.43
▸ SMN1; SMN2 Q16637 7/20 0.43
▸ PKM P14618 1/20 0.43
▸ MAPT P10636 5/20 0.41
▸ APP P05067 1/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ BACE2 Q9Y5Z0 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ KMT2A Q03164 1/20 0.40
▸ F10 P00742 1/20 0.40
▸ KDM4E B2RXH2 4/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ HSD17B10 Q99714 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ DEGS1 O15121 1/20 0.39
▸ GRM1 Q13255 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17805353 0.88 NPC1 (0.43) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12241441 0.88 RAB9A (0.43) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12155451 0.87 ALDH2 (0.44) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12156254 0.86 POLB (0.50) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12155769 0.86 SMN1; SMN2 (0.49) NPC1RAB9ASMN1; SMN2KMT2AKDM4E
SCHEMBL12155520 0.82 L3MBTL1 (0.47) NPC1RAB9ASMN1; SMN2PKMKMT2A
SCHEMBL12241426 0.80 NPC1 (0.44) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12156251 0.80 RAB9A (0.44) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12155501 0.80 NPC1 (0.43) NPC1RAB9ASMN1; SMN2PKMMAPT
SCHEMBL12241425 0.79 PDCD1 (0.47) NPC1RAB9ASMN1; SMN2MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563776-B1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC (US) 2016-06-08 — — EP disclosed
US-20150322012-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM AVENUE CAPITAL MANAGEMENT II, L.P. 2015-11-12 — — US disclosed
US-9120751-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-09-01 — — US disclosed
US-9120751-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-09-01 — — US disclosed
US-8980629-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-03-17 — — US disclosed
US-8980629-B2 Compounds that modulate intracellular calcium CALCIMEDICA, INC. (US) 2015-03-17 — — US disclosed
WO-2011139489-A2 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA INC. (US) 2011-11-10 — — WO disclosed
US-20110263612-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-10-27 — — US disclosed
US-20110263612-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM CALCIMEDICA, INC. (US) 2011-10-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150322012-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885SMN1; SMN2 854/4885
US-20110263612-A1 COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM ORAI1, SARAF, RYR2 NPC1 262/4885RAB9A 1174/4885SMN1; SMN2 854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback